Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00277238
Status:
COMPLETED
Last Update Posted:
2017-03-08
First Post:
2006-01-13
Brief Title:
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder Null And Partial Responder Hepatitis C Virus HCV Genotype 1 Infected Subjects
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
CPG 10101 Combination Therapy for the Treatment of Hepatitis C A Phase II Randomized Open Label Multi-Center Parallel Arm Controlled Trial of CPG 10101 at Two Different Dose Levels With Pegylated-Interferon-Alpha 2B PEG-IFN Plus Ribavirin RBV or PEG-IFN Plus RBV Without CPG 10101 in the Treatment of Non-Responder Null and Partial Responder HCV Genotype 1 Infected Subjects
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B PEG-IFN plus ribavirin RBV compared to PEG-IFN and RBV without CPG 10101 in HCV positive subjects who were classified as non-responders to previous adequate PEG-IFN plus RBV therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CPG 10101-004 | None | None | None |